Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...

The drug is now cleared for use in adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining ...

“Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a new clinical subtype of breast cancer, benefiting from treatment with novel anti-HER2 antibody-drug ...

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer. All patients with breast cancer who may be candidates for antibody-drug ...

The top-line results of DESTINY Breast-04 are impressive - in patients with HER2-low metastatic breast cancer who received multiple lines of prior treatment, Enhertu (trastuzumab deruxtecan ...

Roche has obtained a CE Mark in the EU for a companion diagnostic that can be used to identify patients with HER2-low metastatic breast cancer who may be eligible for treatment with AstraZeneca ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.